Compare Novo Nordisk A/S (NVO) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Occidental Petroleum Corporation — how do they compare? Novo Nordisk A/S trades at $46.04 (market cap $207.85B), while Occidental Petroleum Corporation trades at $58.47 (market cap $55.89B). The key difference: Novo Nordisk A/S is far larger — about 3.7× Occidental Petroleum Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | OXY | |
|---|---|---|
Market Cap | $207.85B | $55.89B |
Sector | Health | Energy |
52-Week High | $63.98 | $66.24 |
52-Week Low | $35.29 | $38.92 |
Enterprise Value | $222.55B | $74.65B |
Dividend Yield | 3.81% | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Occidental Petroleum (OXY) trades at $58.65, up 4.9% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and is focusing on debt reduction while targeting over $4 billion in annual sustainable cash flow by 2030. Valuation ratios remain reasonable with a P/E of 16.49 and EV/EBITDA of 5.26.
The outlook is positive, driven by operational outperformance and higher oil prices, but remains sensitive to commodity volatility. Analyst consensus is a Buy with a $69.33 price target, though execution risks and oil price dependence are key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
